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and a combination of tegafur, gimeracil and oteracil. Across these oncology assess-
ments a total of 19 patient subgroups have been evaluated. Eleven subgroups (58%) 
showed an additional benefit according to the G-BA. Eight subgroups (42%) received 
the rating “no additional benefit” or “less benefit than comparator”. The compara-
tors chosen by G-BA within subgroups vary widely depending on the indication. 
Key factors for the positive outcome of these assessments were increased overall 
survival, reduction of symptoms or improved quality of life. Main reasons for the 
G-BA to attest no additional benefit include inappropriate indirect comparison and 
lack of adequate patient subgroup analysis. ConClusions: Analysis of HTA reports 
in oncology shows that while overall survival is a strong end point, also increased 
quality of life and reduced side-effects can be sufficient to achieve a beneficial 
outcome (crizotinib: considerable benefit). Importantly, the provided data must be 
applicable to the German regulations under AMNOG, showing clinical evidence 
against the specified comparator. The amount of the additional benefit plays an 
important role in the reimbursement amount negotiations following the definition 
of the additional benefit by the G-BA.
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HealtH teCHNology assessmeNt: Is It tHe RIgHt PIeCe foR tHe 
JoRdaNIaN HealtH CaRe Puzzle?
Al Rabayah A.A., Jaddoua S.
King Hussien Cancer Center, Amman, AL, Jordan
objeCtives: To study the pharmaceutical reimbursement/Coverage decision 
making processes in Jordan to highlight the importance of conducting formalized 
technology assessments Methods: To review publically available data regarding 
the reimbursement/Coverage decision making processes in Jordan through search-
ing related organization’s websites and publically available regulations. Results: 
Jordan is characterized with a fragmented health care system. Pharmaceutical 
registration and pricing are under the responsibility of the JFDA. Furthermore, it 
is responsible about medication selection for the Rational Drug List (the national 
formulary). The medication supply chain differs between the public and the private 
sectors in term of process and out puts. The medication selection process is not 
governed by criteria and not empowered by an independent review body to support 
decision making by the national appraisal committee (national P&T). The rational 
drug list is publically available but without details of the decision or the processes 
of decision making process. Listing of new medication is wide without indication 
specification or date of listing. The role of cost-effectiveness is limited and the ten-
der prices are not linked to any type of cost effectiveness analysis ConClusions: 
The National Agenda, the National health Policy and the National Drug Policy 
tackled the high health expenditure in Jordan as an essential priority. This chal-
lenged is due to the characteristics of the Jordanian health care system that is 
fragmented with a divided funding system between public and private sectors. A 
more formalized medication selection processes empowered with drug information 
services that provide evidence based data and analysis in the form of technology 
assessment would play a role in decreasing health care expenditures. All of these 
recommendations should move parallel with improving the level of transparency 
and patient engagement.
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ePIdemIology foR oNCologICal dRugs RegaRdINg tHe BeNefIt dossIeR 
PRePaRatIoN IN geRmaNy
Kürschner N., Schmitter S.
Pfizer Deutschland GmbH, Berlin, Germany
objeCtives: An early benefit assessment of drugs after launch has been imple-
mented since 2011 in Germany. The Institute for Quality and Efficiency in Health Care 
(IQWiG) assesses the benefit of the drug based on a dossier submitted by the phar-
maceutical manufacturer. Based on this assessment and the statements by industry, 
scientific community and patient organizations the Federal Joint Committee (G-BA) 
reviews and decides on the extent of the additional benefit. The dossier needs also 
to contain information about the number of patients treated with the new drug. The 
objective is to investigate the sources considering the calculation of patient numbers 
for oncological drugs. Methods: A review of oncological drugs which passed through 
the benefit assessment was conducted to evaluate which data sources and methods 
were used to calculate the potential patient number. The results were compared with 
IQWiG’s assessment and the final decision by G-BA, to detect possible methodologi-
cal difficulties. Results: The data sources regarding German epidemiological data 
were mainly collected through publicly available sources such as national and local 
cancer registries. Difficulties occurred with small cancer entities or when specific 
data regarding patient subpopulations (e.g. through age, tumor stages, ECOG perfor-
mance status or previous therapies) was needed. The pharmaceutical manufacturer’s 
calculations were often challenged by IQWiG and G-BA without suggesting a precise 
alternative or more suited data source. ConClusions: The data collection and data 
availability within the benefit dossier process for oncological drugs is in most cases 
challenging and the efforts needed should not be underestimated. Authorities, indus-
try and medical community should work on a common solution for a more valid and 
reliable calculation of the potential patient number in oncology.
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eCoNomICal losses due to dIsaBlemeNtPaReNts CaRRINg foR CHIldReN 
wItH oNCoHematologICal dIseases
Ganieva D.1, Zhukovskaya E.1, Spichak I.2
1Federal Scientific Centre of Children Hematology, Oncology, Immunologyl, Moskow, Russia, 
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objeCtives: Socio-economic phenomena, caused by disease of children are reflected 
primarily in the formation of non-medical costs. Methodology for calculation of non-
medical costs includes a number of parameters, including the cost of lost output 
by persons caring for children during the treatment period. Methods: The study 
involved patients from Oncohematological Chelyabinsk Center for Children and 
Adolescents behalf of prof. V. Gerein been treated in the period from 2008 to 2013. 
10, respectively). Similarly, patients admitted to hospital with oesophageal cancer 
experienced a high 90-day mortality rate, ranging from 22% to 21.9% in 2007-08 and 
2009-10, respectively. However, between 2006 and 2010, no therapies were submitted 
for NICE appraisal for oesophageal cancer, suggesting that there may have been a 
lack of research interest and potentially explaining why there was no substantial 
decrease in mortality from 2007, as compared to indications where therapies had 
been approved, such as lung, colon and breast cancer. ConClusions: The recom-
mendation of therapies and their uptake in the UK may at least partially explain the 
trends noted in this study, although other factors such as delay in therapy uptake 
and off-label use may also need to be taken into account.
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do NICe evIdeNCe RevIew gRouPs (eRg) foCus oN dIffeReNt asPeCts of 
maNufaCtuReR suBmIssIoNs IN oNCology?
Heemstra L., Sweeney N., Van Engen A.
Quintiles, Hoofddorp, The Netherlands
objeCtives: Evidence Review Groups (ERGs) provide a critical appraisal of the manu-
facturer submission in the NICE single technology appraisal (STA) process. As the aca-
demic centres may differ in experience and methodology, the objective of this study was 
to evaluate whether the focus areas and key criticisms differ between ERGs. Methods: 
The NICE website was searched for all NICE oncology STAs, published between June 
2010 and June 2013. The ERG reports were retrieved, and the main critiques were cat-
egorised for the five centres that performed the most evaluations. The focus areas of the 
ERGs were further studied. Results: A total of 27 STAs were identified with evaluations 
performed by 9 different ERGs. The most evaluations were performed by Liverpool (9), 
followed by Sheffield (4), and PenTAG, West Midlands and York (3 evaluations each). All 
ERGs would report uncertainties related to the extrapolation and gain in overall survival 
(OS), maturity of data, trial comparator, and the quality of life (QoL) data. In addition all 
critiques covered submission quality and disease specific challenges, yet variation was 
found in focus area between ERGs. For example a specific focus area of Liverpool was 
the OS modelling method. Proposed changes to survival modelling included separating 
the survival curves for pre- and post-progression, and removing any survival advan-
tage post-progression where this was considered inappropriate. Comments from other 
agencies on OS were mainly limited to the choice of parametric survival function. Other 
areas that differed between ERGs were the systematic review methods (more often 
reported by Sheffield) and comments on the QoL data (York). ConClusions: Although 
all ERGs focus on uncertainty around the evidence and quality of the manufacturer 
submissions, the focus areas differed between the groups. The key difference seems 
to relate to research focus of the academic centre.
PCN209
RevIew of NICe teCHNology aPPRaIsals IN oNCology: How does 
ClINICal evIdeNCe CHaNge oveR tIme?
Dequen P., Cooper N.J., Abrams K.R.
University of Leicester, Leicester, UK
Drug licensing and reimbursement authorities worldwide are considering new 
ways to stimulate market access for innovative medicines such as accelerated 
approval and conditional coverage. Early release of pharmaceuticals calls for more 
responsive decision-making alongside continuous evidence generation through-
out clinical development. We explore whether changing trends in clinical evidence 
considerations for health technology assessment (HTA) by the National Institute 
for Health and Care Excellence (NICE) may help inform future evidence require-
ments for rapid and early HTA. objeCtives: We investigate how the submission 
and acceptability of clinical evidence for single, multiple and repeated assessments 
of cancer drugs by NICE have changed in the past decade. Methods: We reviewed 
technology appraisals published online since February 2002 by NICE for pharma-
ceuticals in oncology. Information regarding the clinical evidence included and the 
methods used to analyse relative treatment effects across relevant comparators 
was extracted. Manufacturer submissions, assessment reports, and final appraisal 
determinations were considered for longitudinal comparison. Results: Out of a 
total of 254 appraisals identified since 2002, 85 assessed cancer drugs and 76 of 
these were included for review based on available documentation. Only 11 prod-
ucts had been re-assessed to date with initial guidance superseded by a multiple 
technology appraisal or clinical guideline. We found a greater reliance on phase 
II and observational data in recent appraisals, particularly for novel therapies in 
areas of high unmet need. Limited data was also accompanied by an increase use 
of surrogate outcomes and extrapolation of observed short-term clinical benefits. 
Recent submissions were also marked by the uptake of network meta-analysis 
methodologies. ConClusions: NICE has previously recommended cancer drugs 
based on immature clinical data allowing for considerable uncertainty in ‘real-
world’ effectiveness estimates. However, these examples remain the exception to 
the rule; moreover our review highlighted a need for methodological development 
to deal with early clinical evidence.
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g-Ba assessmeNts of oNCology tRIals: Is INCReased oveRall suRvIval 
a “must Have”?
Schuchardt M.1, Nijhuis T.1, Friedmann B.2
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Mannheim, Germany
objeCtives: Objective of this research was to provide an overview of Health 
Technology Assessments (HTAs) in oncology after introduction of AMNOG in 
Germany. Methods: Quintiles’ HTA database (HTA Watch) has been used to ana-
lyse HTAs in Germany. The timeframe chosen for analysis was 1st of January 2011 
to 24th of June 2013. All reports have been analysed in detail to reveal key factors for 
success or failure, which are presented in the following. Results: Since introduc-
tion of AMNOG in 2011, thirty percent (13 out of 43) of all completed assessments by 
the G-BA (Federal Joint Committee) evaluated cancer drugs. The products assessed 
were abiraterone acetate, axitinib, brentuximab vedotin, cabazitaxel, crizotinib, 
decitabine, eribulin, ipilimumab, pixantrone, ruxolitinib, vandetanib, vemurafenib 
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objeCtives: To evaluate European physicians’ treatment preferences for prevent-
ing skeletal-related events (SREs) in patients with bone metastases from solid 
tumors. Methods: Physicians completed an online discrete-choice experiment 
survey consisting of 10 choices between pairs of hypothetical medication profiles 
for a putative patient. Each profile included five attributes within a pre-defined range 
(based on prescribing information for the available bone-targeted agents [BTA]): 
months until first SRE (10, 18 and 28 months); months until worsening of pain (3, 6 
and 10 months); annual risk of osteonecrosis of the jaw (ONJ; 0, 1 and 5%); annual risk 
of renal impairment (0, 4 and 10%); and mode of administration (oral tablet, subcuta-
neous injection, 15-minute infusion and 120-minute infusion). Choice questions were 
based on an experimental design with known statistical properties. The survey was 
pretested with 8 physicians using open-ended interviews. A separate main-effects 
random parameters logit model was estimated for each country. Results: Physicians 
from France (n= 191), Germany (n= 192) and the UK (n= 197) completed the survey. 
Among the attributes included in the survey, months until first SRE and the risk of 
renal impairement were the most important attributes in France and the UK, whereas 
in Germany months until first SRE and a delay in worsening of pain were the most 
important. For all these attributes, better levels were significantly preferred to worse 
levels (p< 0.05). In all three countries, a 120-minute infusion every 4 weeks was the 
least preferred mode of administration (p< 0.05). The annual risk of ONJ was judged by 
physicians to be the least important attribute in all three countries. ConClusions: 
Physicians generally make treatment decisions regarding choice of BTA for patients 
with bone metastases based on intent to delay the onset of SREs, managing risk of 
renal impairment and preventing the worsening of pain.
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NuRses’ PRefeReNCes foR BoNe metastases tReatmeNts IN tHe uNIted 
states
Mohamed A.F.1, Qian Y.2, Hauber A.B.1, Collins H.2, Hechmati G.3, Gatta F.3, Arellano J.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 
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objeCtives: Several bone-targeted agents (BTAs) are approved for the prevention 
of skeletal related events (SREs). Nurses work closely with physicans and patients 
in managing the disease. Whilst influencing treatment decisions, nurses prefer-
ences for alternative treatment options have not been assessed. This study evalu-
ated US nurses’ preferences for treatment attributes in preventing SREs among 
patients with bone metastases from solid tumors. Methods: Nurses completed a 
web-enabled discrete-choice experiment survey consisting of 10 choices between 
pairs of hypothetical medication and patient profiles. Each profile included six 
medication attributes within a pre-defined range (primarily based on prescribing 
information and real-world practice): months until first SRE (10, 18 and 28 months); 
months until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis of 
the jaw (ONJ; 0, 1 and 5%); annual risk of renal impairment (0, 4 and 10%); mode of 
administration (subcutaneous injection, 15-minute infusion and 120-minute infu-
sion); and out-of-pocket cost to patients ($25, $75, $150 and $330). Choice questions 
were based on an experimental design with known statistical properties. The survey 
was pretested with 6 nurses using open-ended interviews. A main-effects random 
parameters logit model was estimated. Results: A total of 196 US nurses com-
pleted the survey. Among the attribute levels included in the survey, out-of-pocket 
costs to patients, risk of renal impairement, and months until first SRE were the 
most important attributes. For all attributes, better levels were significantly pre-
ferred to worse levels (p< 0.05) except that no difference was observed between 0% 
and 1% ONJ attribute. Annual risk of ONJ was perceived by nurses to be the least 
important attribute. ConClusions: When working with physicians and patients 
on the choice of BTAs for patients with bone metastases, out-of-pocket costs to 
patients, managing the risk of renal impairment and delaying time to first SRE are 
the primary foci for nurses.
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uNIted states
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objeCtives: Among the bone-targeted agents (BTAs) currently approved for the pre-
vention of skeletal-related events (SREs), several characteristics may be considered 
by physicians when making treatment decisions. This study evaluated US physi-
cians’ treatment preferences for preventing SREs in patients with bone metastases 
from solid tumors. Methods: Physicians treating patients with bone metasta-
ses completed a web-enabled discrete-choice experiment survey consisting of 10 
choices between pairs of hypothetical medication and patient profiles. Each profile 
included six medication attributes within a pre-defined range (primarily based on 
prescribing information and real-world practice): months until first SRE (10, 18 and 
28 months); months until worsening of pain (3, 6 and 10 months); annual risk of 
osteonecrosis of the jaw (ONJ; 0%, 1% and 5%); annual risk of renal impairment (0%, 
4% and 10%); mode of administration (subcutaneous injection, 15-minute infusion 
and 120-minute infusion every 4 weeks); and out-of-pocket cost to patients ($25, 
$75, $150 and $330). Choice questions were based on an experimental design with 
known statistical properties. The survey was pretested with 8 physicians using 
open-ended interviews. A main-effects random parameters logit model was esti-
mated. Results: A total of 200 US physicians completed the survey. Among the 
attribute levels included, out-of-pocket cost to patients, months until first SRE and 
the risk of renal impairment were the most important attributes. For those attrib-
utes, better levels (outcomes) were significantly preferred to worse levels (P < 0.05). 
For mode of administration, subcutaneous injection was preferred over 15-minute 
infusion every 4 weeks (P < 0.05). ConClusions: When making treatment deci-
sions regarding choice of BTA for patients with bone metastases, out-of-pocket cost 
to patients, delaying the onset of SREs and managing the risk of renal impairment 
are the primary foci for physicians.
Patient selection was random. The basic condition for inclusion in the study was the 
availability of data necessary to meet the costs. The number of patients at this stage 
of the study was already 42 people. Age at diagnosis was 9 months to 12 years, the 
median age of the patients was 6,4 ± 5,6 years. All of the patients were in the hospi-
tal with their parents of working age. In the calculations have been included: - GRP 
Chelyabinsk region (Gross Regional Product-14 USD per day per capita ) and GDP 
(Gross Domestic Product-44,4 USD per day per capita ), which amounted on average in 
2008-2012. The formula for the calculation of total costs:E $ = Nd x GRP / GDP (Nd-the 
number of days of disability) Results: Comparing the various cost components of 
treatment revealed that the indirect costs are 66% of the total amount of all expenses 
for medical treatment. State losses caused by non-working period of hospitalized for 
care people and non-produced Gross Regional Product are 7758,5 ± 1076,1 USD per 
capita. Losses of GDP are 21449,6 ± 3748,8 USD per capita. ConClusions: The for-
mation of regional budgets should be done with consideration of big loss connected 
with disability of people hospitalized for the care of the a sick child, adjusted for and 
with GRP/GDP taken into account of big potion non-medical costs.
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PoPulatIoN Based utIlIzatIoN of RadIatIoN tHeRaPy By a CaNadIaN 
BReast CaNCeR CoHoRt
Mittmann N.1, Seung S.J.1, Liu N.1, Porter J.1, Saskin R.1, Hoch J.2, Evans W.3, Leighl N.4, Trudeau 
M.5, Earle C.C.6
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objeCtives: To examine the trends in radiation therapy (RT) utilization by a popula-
tion based breast cancer cohort in Ontario, Canada. Methods: The provincial can-
cer registry maintains cancer specific databases and provided a breast cancer cohort 
based on diagnosis dates from April 1, 2005 to March 31, 2010. Staging information 
was also available. The cohort was then linked, by their encrypted health card num-
ber, to linkable administrative datasets that are maintained by the Institute for 
Clinical Evaluative Sciences (ICES) such as RT utilization. Results: An all female 
breast cancer cohort (N= 39,656) was identified over a five-year timeframe and the 
average age was 61.6 ± 14.0 years. Approximately, two thirds (N= 25,225) of patients 
received RT and staging information was available for 22,988 patients (stage I = 
9,541; stage II = 8,516; stage III = 4,050; and stage IV = 881). Patients had an average 
of 1.4 ± 0.7 (stage I) number of RT courses, 1.8 ± 1.1 (stage II), 2.5 ± 1.3 (stage III), and 
2.8 ± 2.4 (stage IV). The percent ratio of conventional RT to intensity modulated RT 
(IMRT) was 70.9%:16.6% (stage I), 71.6%:11.3% (stage II), 74.6%:4.6% (stage III), and 
72.7%:12.6% (stage IV). For the non-IMRT cohort with a primary cancer (N= 30,887), 
the average number of fractions per course was 18.1 ± 9.2. ConClusions: From 
2005 – 2010, almost two thirds of a Canadian female breast cancer cohort received 
RT and the average number of courses increased with stage. A similar trend was 
observed with the type of RT (coventional RT utilization increased with stage) but 
peaked at stage III and decreased at stage IV, likely due to palliation. The next step 
is to apply unit costs to the number of fractions per subgroup and to also obtain 
RT-planning and radiation therapist times.
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defININg elIgIBle PatIeNt PoPulatIoN IN são Paulo state Based oN 
CleoPatRa tRIal INClusIoN CRIteRIa: a RetRosPeCtIve aNalysIs of 
fuNdação oNCoCeNtRo (fosP) CaNCeR PatIeNt RegIstRy (RegIstRo 
HosPItalaR do CâNCeR – RHC)
Tobaruella F.S., Maximo M.F.M., Tsuchiya C.T., Buschinelli C.T., Gonçalves T.M.
Roche Brazil, São Paulo, Brazil
objeCtives: Breast cancer (BC) is the most common cancer affecting women and, 
despite advances in treatment, is still the leading cause of cancer death among 
women worldwide. Approximately 20%-25% of the women diagnosed with BC will 
have HER2-positive disease and those with metastatic disease (mBC) have a 5-year 
life expectancy of only 24%. Recently, pertuzumab (P) was approved as a new thera-
peutical option for first line HER2-positive mBC in Brazil. This study aims to define 
the proportion of BC patients that would be eligible for pertuzumab+trastuzumab+
chemotherapy (P+T+C) combination therapy in São Paulo state by analyzing retro-
spectively (2000-March 2013) the Fundação Oncocentro (FOSP) cancer patient registry 
(Registro Hospitalar de Câncer – RHC). Methods: Raw data of cancer cases reported 
from 2000-March 2013 was taken from the FOSP-RHC and mined according to the 
inclusion criteria of the CLEOPATRA trial. Only women with histologically/cytologi-
cally confirmed diagnosis of BC (ICD-50) and reported TNM classification at diagnosis 
were included in the analysis. P+T+C therapy eligible patients were those reported 
as stage IV at diagnosis (de novo mBC) or stages 0, I, II and III with evidence of pro-
gression at last tumour assessment (recurrent cases), excluding ones with evidence 
of central nervous system (CNS) metastasis. Was considered that all patients in the 
database would test for HER2 status and positivity rate was taken from literature 
(25%). Results: During the analysis period 59,095 BC cases with TNM classification 
at diagnosis were reported. 4,660 cases were considered de novo mBC and 7,378 cases 
were considered as recurrent. According to the positivity rate 3,010 patients would be 
eligible for P+T therapy which accounts for approximately 5.1% of the overall cases 
of BC. ConClusions: First-line HER2-positive mBC is a targeted, clearly defined and 
limited patient population where pertuzumab based regimen provides significant 
and clinically meaningful benefits in overall survival and progression-free-survival.
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